As insurers sweat over whether the Trump administration will continue funding cost-sharing subsidies for low-income enrollees, 16 state attorneys general have asked a federal appeals court to let them intervene in a legal case to keep those payments flowing.
Increasing competition, reforming outdated laws, improving data infrastructure and letting market forces work are key to lowering drug costs, according to a new paper.
Up to 6.3 million people could end up paying substantially higher premiums if a bill similar to the House's Obamacare replacement becomes law, according to the Kaiser Family Foundation.
Many long-term care providers may not be prepared to meet CMS emergency preparedness requirements—the cost of which is estimated at $370 million the first year.
National challenge, budget bill could spur action on patient identification and patient matching.
The U.S. Supreme Court ruled on Monday that Kindred Healthcare could enforce a binding arbitration agreement with the families of two former residents of its nursing homes.
The Senate Finance Committee is slated to hold a hearing Tuesday on legislation aimed at improving care for Medicare beneficiaries with chronic conditions.
CareCore National, a healthcare utilization management company, has agreed to pay $54 million to settle allegations it fraudulently billed the CMS.
The Trump administration hinted to consumer organizations last week that it may repeal an Obama-era regulation that prohibits nursing homes from requiring patients to enter binding arbitration agreements.
The rising prices of branded drugs are affecting consumers, providers and payers alike, which have seen drug prices jump 18% every year since 2010.
Washington's and New Mexico's state attorneys general will probe Eli Lilly's insulin product prices as well as the company's relationship with pharmacy benefit managers. The price of insulin has been steadily increasing over the past decade.
The Trump administration and GOP legislators have touted cross-state sales of insurance as a way to promote competition and rein in rising premiums. The theory is untested.